A Randomized, Double-blind, Placebo-controlled, 2-period Crossover Study of BPN14770 in Adult Males With Fragile X Syndrome
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs BPN 14770 (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Sponsors Tetra Therapeutics
- 10 Sep 2019 Planned End Date changed from 31 Aug 2019 to 31 Dec 2019.
- 10 Sep 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Dec 2019.
- 05 Aug 2019 According to a Tetra Discovery Partners media release, Tetra Discovery Partners changed its name to Tetra Therapeutics.